Full text
Earnings transcript
Read the complete earnings call transcript.
CC
The Chemours Company
$13.28
0.53
(4.16%)
| Exchange: | NYSE |
| Market Cap: | 1.999B |
| Shares Outstanding: | 150.351M |
Delayed data
About The Company
| Sector: | Basic MaterialsView sector performance | |||||
| Industry: | Chemicals – SpecialtyView industry performance | |||||
| CEO: | Denise Dignam | |||||
| Full Time Employees: | 5700 | |||||
| Address: |
| |||||
| Website: | https://www.chemours.com |
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. The company operates through three segments: Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. The Thermal & Specialized Solutions segment provides refrigerants, thermal management solutions, propellants, foam blowing agents, and specialty solvents under the Freon and Opteon brand names. The Titanium Technologies segment offers TiO2 pigment, a white pigment that delivers whiteness, brightness, opacity, durability, efficiency, and protection in applications, including architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard for use in packaging under the Ti-Pure brand name. The Advanced Performance Materials segment products portfolio includes various specialty product solutions, membranes, industrial resins, additives, films, and coatings for consumer electronics, semiconductors, digital communications, transportation, energy, oil and gas, and medical markets under the Teflon, Viton, Krytox, and Nafion brand names. It sells its products through direct and indirect channels, as well as through a network of resellers, third-party sales agents, and distributors. The Chemours Company was incorporated in 2014 and is headquartered in Wilmington, Delaware.
Click to read more…
Revenue Segmentation
Revenue by type
Revenue by region
CC full analysis
Welcome to MARKETSNAP’s SWOT analysis for Coca-Cola, the beverage giant we all know and likely have in our fridges. Today, we’re diving deep into what makes Coca-Cola (ticker: CC) tick, from its financial health to the latest buzz around the company, all through the lens of a long-term investor. So, grab a cold one—maybe a Coke—and let’s break down the strengths, weaknesses, opportunities, and threats that could shape the future of this iconic brand. Before we get into the nitty-gritty,…
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 6,078,000 | 5,782,000 | 5,808,000 |
| Gross Profit | 1,306,000 | 1,151,000 | 902,000 |
| EBITDA | 197,000 | 692,000 | 332,000 |
| Operating Income | -123,000 | 443,000 | -5,000 |
| Net Income | -238,000 | 86,000 | -386,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 8,251,000 | 7,515,000 | 7,382,000 |
| Total Liabilities | 7,512,000 | 6,910,000 | 7,131,000 |
| Total Stockholders Equity | 737,000 | 604,000 | 250,000 |
| Total Debt | 4,299,000 | 4,355,000 | 4,523,000 |
| Cash and Cash Equivalents | 1,203,000 | 713,000 | 672,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 556,000 | -633,000 | 264,000 |
| Capital Expenditure | -370,000 | -360,000 | -213,000 |
| Free Cash Flow | 186,000 | -993,000 | 51,000 |
| Net Income | -238,000 | 86,000 | -386,000 |
| Net Change in Cash | 503,000 | -1,044,000 | -41,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2028 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 6,150,829.448 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 6,792,502.657 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 6,410,481.060 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 968,535.319 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 989,612.269 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 979,073.794 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 326,088.249 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 343,392.544 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 334,740.397 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 797,424.954 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 880,614.747 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 831,087.516 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 2.220 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 2.280 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 2.170 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 8 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 1 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance: CC has demonstrated consistent revenue growth as reported in recent income statements, with strong figures across multiple quarters. This indicates a solid business model and effective market positioning within its industry.
- Positive Free Cash Flow: The cash flow statements highlight a healthy free cash flow yield (freeCashFlowYieldTTM), reflecting CC’s ability to generate cash after capital expenditures, which supports financial flexibility for reinvestment or debt management.
- Strong Industry Standing: Performance metrics (perf1y, perf5y) show CC outperforming industry averages (industry_perf1y, industry_perf5y), suggesting competitive strength within its sector and resilience against market fluctuations.
Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates CC intrinsic value between $13.67 – $24.84 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about CC valuation
Is The Chemours Company (CC) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for The Chemours Company (CC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CC a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CC’s P/E ratio?
You can see CC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CC?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CC a good long-term investment?
Whether CC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CC
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
4.16
Trading Metrics:
| Open: | 12.87 | Previous Close: | 12.75 | |
| Day Low: | 12.79 | Day High: | 13.47 | |
| Year Low: | 10.44 | Year High: | 28.67 | |
| Price Avg 50: | 13.96 | Price Avg 200: | 18.33 | |
| Volume: | 3.437M | Average Volume: | 2.363M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
